Acurx filed a provisional patent application with the U.S. Patent and Trademark Office for use of ibezapolstat to treat C. difficile Infection (CDI) while reducing recurrence of infection and improving the health of the gut microbiome.
In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI.
The Company...
